A detailed history of Morgan Stanley transactions in Vaccitech PLC stock. As of the latest transaction made, Morgan Stanley holds 8,873 shares of VACC stock, worth $30,256. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,873
Previous 12,862 31.01%
Holding current value
$30,256
Previous $43,000 30.23%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
N/A
-3,989 Reduced 31.01%
8,873 $30,000
Q1 2024

Aug 16, 2024

SELL
$3.41 - $3.7 $12,293 - $13,338
-3,605 Reduced 21.89%
12,862 $43,000
Q1 2024

May 15, 2024

SELL
$3.41 - $3.7 $12,293 - $13,338
-3,605 Reduced 21.89%
12,862 $43,000
Q4 2023

Aug 16, 2024

BUY
$2.72 - $5.0 $20,655 - $37,970
7,594 Added 85.59%
16,467 $60,000
Q4 2023

Feb 13, 2024

SELL
$2.72 - $5.0 $12,914 - $23,740
-4,748 Reduced 22.38%
16,467 $60,000
Q3 2023

Nov 15, 2023

BUY
$1.68 - $3.16 $9,690 - $18,226
5,768 Added 37.34%
21,215 $65,000
Q2 2023

Aug 14, 2023

SELL
$2.06 - $2.51 $109,901 - $133,908
-53,350 Reduced 77.55%
15,447 $31,000
Q1 2023

May 15, 2023

BUY
$2.16 - $3.15 $123,081 - $179,493
56,982 Added 482.29%
68,797 $154,000
Q4 2022

Feb 14, 2023

SELL
$2.1 - $2.68 $1,581 - $2,018
-753 Reduced 5.99%
11,815 $27,000
Q3 2022

Nov 14, 2022

SELL
$3.06 - $6.19 $3,797 - $7,681
-1,241 Reduced 8.99%
12,568 $40,000
Q2 2022

Oct 27, 2022

BUY
$3.09 - $6.21 $13,938 - $28,013
4,511 Added 48.52%
13,809 $61,000
Q2 2022

Aug 15, 2022

BUY
$3.09 - $6.21 $13,938 - $28,013
4,511 Added 48.52%
13,809 $61,000
Q1 2022

Oct 27, 2022

SELL
$4.51 - $11.75 $20,344 - $53,004
-4,511 Reduced 32.67%
9,298 $48,000
Q1 2022

May 13, 2022

SELL
$4.51 - $11.75 $1,501 - $3,912
-333 Reduced 3.46%
9,298 $48,000
Q4 2021

Feb 14, 2022

SELL
$8.98 - $15.55 $129,698 - $224,588
-14,443 Reduced 59.99%
9,631 $107,000
Q3 2021

Nov 15, 2021

BUY
$14.0 - $16.5 $337,036 - $397,221
24,074 New
24,074 $379,000

Others Institutions Holding VACC

About Vaccitech plc


  • Ticker VACC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,216,200
  • Market Cap $127M
  • Description
  • Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B...
More about VACC
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.